Actelion’s Opsumit drug missed trial endpoint: doctor | International News Live Blog

https://internationalnewsliveblog.wordpress.com/2017/01/23/actelions-opsumit-drug-missed-trial-endpoint-doctor/

ZURICH (Reuters) – Actelion’s Opsumit drug missed a primary endpoint in a late-stage study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, a doctor involved in the trial said in a statement from the Swiss drugmaker. http://internationalnewslive.com/actelions-opsumit-drug-missed-trial-endpoint-doctor/